Shareholders Notified of August 4, 2026 Lead Plaintiff Deadline in Grail Lawsuit
A securities class action lawsuit is underway against Grail, Inc. (NASDAQ: GRAL) for alleged misleading disclosures regarding the NHS-Galleri trial between May 13, 2025, and February 19, 2026. The case claims that Wall Street analysts built their models on optimistic company statements about the clinical trial's results, which later proved to be incomplete or inaccurate when Grail failed to meet its primary endpoint in late-February 2026. On February 20, 2026, GRAL shares fell by $51.32 per share (a drop of over 50%) following the disclosure that the trial did not achieve statistically significant results for Stage III–IV cancer reduction. The lawsuit argues this led to a sudden reassessment and downgrades from analysts who had previously relied on Grail's assurances about its clinical data. The lead plaintiff deadline is set for August 4, 2026. Investors are being urged by Levi & Korsinsky LLP to submit information if they qualify as part of the class period.
Topics: analyst downgrades class action lawsuit GRAL stock decline